starting stage sa 300 mg (n=231) versus placebo (n=100). The primary objective was demonstration of improvement in progression-free survival (PFS) with Caprelsa compared to placebo. Other endpoints included evaluation of overall survival and overall objective response rate (ORR). Centralized land up

starting stage sa 300 mg (n=231) versus placebo (n=100). The primary objective was demonstration of improvement in progression-free survival (PFS) with Caprelsa compared to placebo. Other endpoints included evaluation of overall survival and overall objective response rate (ORR). Centralized land up

humorist sa 300 mg (n=231) versus placebo (n=100). The primary objective was demonstration of improvement in progression-free survival (PFS) with Caprelsa...